



Confidio Consulting Services Report FELRA & UFCW VEBA Fund

December 5, 2022

Confidio Consulting Service Changes

Background Information



- Confidio, LLC was acquired in September 2021 by RxBenefits, a privately owned pharmacy benefits optimizer ('PBO').
- Following the acquisition, Confidio Consulting Services ('CCS') continued to operate as a free-standing business unit of RxBenefits.
- Since that time, channel conflicts between RxBenefits' clients (which include large, national brokerage and consulting firms) and CCS have challenged our ability to grow the consulting practice.
- RxBenefits has decided to phase out CCS consulting services by Q'1 2023.
- Confidio and RxBenefits are committed to completing all outstanding deliverables due to the FELRA & UFCW VEBA Fund (the 'Fund').
- A proposed transition plan is included on page 3.

Transition Plan for the Fund

Proposed timing and approach



- Outstanding deliverables to the Fund include:
 - Negotiation of the Fund's PBM contract with ESI
 - SaveOnSP impact report (drug level savings) attributable to changes with AbbVie terms and conditions.
- Nancy Eid, Principal Advisor will continue to serve as the Fund's primary contact until 12/30/2022*
 - Deliverables due to the Fund after December 30th will be completed by an RxBenefits colleague with expertise in pharmacy benefits management and contract negotiations.

Transition Plan for the FELRA & UFCW VEBA Fund		
Tasks		Status
Complete negotiation of the 2022-2025 PBM Contract	See Project Plan on page 5.	Waiting for receipt of Draft v1.
Facilitate Transition to RxBenefits Principal Advisor	Send bio and contact information for designated Principal Advisor ('PA') to the Fund; facilitate introduction as needed or requested.	Facilitate transition no later than December 26, 2022.
Terminate or Assign the Fund's contract with Confidio	Collaborate with Fund Co-Counsel and Associated Administrators to develop a plan for terminating the contract, including handling of confidential information.	Initial discussion with Co-Counsel 12/1/2022; follow-up call with Associated Administrators and Co-Counsel pending.

*N Eid has accepted a pharmacy consulting position with Segal, effective January 3, 2023.

PBM PROCUREMENT PROJECT STATUS UPDATE

PBM PROCUREMENT PROJECT STATUS



KEY MILESTONES		START DATE	END DATE	STATUS
7.0	ESI Contract Negotiations	12/1/2022	1/20/2023	Updated 12/5/2022
	Edit Draft v1; submit to Fund Co-Counsel			Waiting for receipt from ESI
	Call with Fund Co-Counsel to review Draft v1 edits			
	Conference call with ESI to discuss Draft v1 edits			
	Edit Draft v2; submit to Fund Co-Counsel			
	Call with Fund Co-Counsel to review Draft v2 edits			
	Conference call with ESI to discuss Draft v2 edits			
	Review final executable draft; submit to Fund Co-Counsel			
	Submit for signature - ESI and the Fund			